Orum begins patient dosing in a phase 1 trial of ORM-5029 to treat HER2-expressing advanced solid tumours
Orum Therapeutics, a private biotechnology company pioneering the development of tumour-directed targeted protein degraders (TPDs), announced that the first patient has been dosed with ORM-5029 in a phase 1 clinical trial for patients with HER2-expressing advanced solid tumours.
ORM-5029 is one of two lead programs from the company
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!